Papillary Thyroid Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Papillary Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 75% to 85% of all cases. It affects more women than men and can occur at any age, but especially between 30 and 50 years old. PTC is usually slow-growing and well-differentiated, meaning it resembles normal thyroid cells. However, it can also spread to the lymph nodes in the neck or other parts of the body. The main symptom of PTC is a painless lump or nodule on the thyroid gland, which can be detected by physical examination or ultrasound. The diagnosis of PTC is confirmed by a fine needle aspiration (FNA) biopsy, which samples cells from the nodule for microscopic analysis. The treatment of PTC depends on the size, stage, and aggressiveness of the tumor, but it usually involves surgery to remove the thyroid gland (thyroidectomy) and radioactive iodine therapy to destroy any remaining cancer cells. PTC has a very good prognosis, with a survival rate of over 90% after 10 years.
The Papillary Thyroid Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Papillary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Papillary Thyroid Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Papillary Thyroid Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 35 molecules, with 32 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Papillary Thyroid Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Papillary Thyroid Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Papillary Thyroid Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AffyImmune Therapeutics IncAlphamab Oncology
Aminex Therapeutics Inc
Arch Oncology Inc
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
BioMed Valley Discoveries Inc
Boston Children's Hospital
Exelixis Inc
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Loxo Oncology Inc
Mersana Therapeutics Inc
Novartis AG
Nuvalent Inc
Osaka University
Pfizer Inc
Purple Biotech Ltd
Recordati SpA
Salubris Biotherapeutics Inc
Suzhou SmartNuclide Biopharmaceutical Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Synactix Pharmaceuticals Inc
Verastem Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Papillary Thyroid Cancer reports